Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Conclusions and clinical perspectives

Date

10 Oct 2016

Session

Biomarker strategies to improve the treatment of castration-resistant prostate cancer

Presenters

Felix Feng

Authors

F. Feng

Author affiliations

Radiation Oncology, University of Michigan, 48109-5010 - Ann Arbor/US

More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

10 Oct 2016

What is the role of CTCs?

Presenter: Howard Scher

Session: Biomarker strategies to improve the treatment of castration-resistant prostate cancer

Resources:

Presentation

Webcast

10 Oct 2016

Using circulating tumour DNA studies to improve the management of prostate cancer patients

Presenter: Gerhardt Attard

Session: Biomarker strategies to improve the treatment of castration-resistant prostate cancer

Resources:

Presentation

Webcast

10 Oct 2016

Translating the genomics landscape into clinical practice

Presenter: Rob Bristow

Session: Biomarker strategies to improve the treatment of castration-resistant prostate cancer

Resources:

Presentation

Webcast

10 Oct 2016

Introduction

Presenter: David Olmos

Session: Biomarker strategies to improve the treatment of castration-resistant prostate cancer

Resources:

Webcast